Business Context and Reporting Period
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapies for significant unmet medical needs. The unaudited Form 10-Q covers the three and nine months ended September 30, 2020, with comparisons to the corresponding 2019 periods. The company had no approved products or product sales and operated as a single segment.
- Primary clinical programs: PTG-300 for blood disorders, including polycythemia vera; PN-943 for ulcerative colitis; and PTG-200 and second-generation IL-23 receptor antagonists under the Janssen collaboration.
- PTG-300 development was redirected toward polycythemia vera after discontinuation of development for beta-thalassemia and myelodysplastic syndromes.
- As of September 30, 2020, the company had 76 full-time equivalent employees, including 57 in research and development.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| License and collaboration revenue | $13.1 million | $23.0 million |
| Research and development expense | $16.0 million | $55.0 million |
| General and administrative expense | $4.9 million | $13.6 million |
| Loss from operations | $(7.8) million | $(45.7) million |
| Net loss | $(7.8) million | $(47.3) million |
| Net loss per share | $(0.21) | $(1.45) |
| Cash used in operating activities | Not separately provided for the quarter | $(53.6) million |
- Revenue was entirely license and collaboration revenue from Janssen; the filing does not report product revenue.
- Revenue exceeded operating expenses in the third quarter, but the company remained loss-making because of its development-stage cost structure and other expenses.
- Cash, cash equivalents and marketable securities totaled approximately $200.0 million at September 30, 2020, including $83.6 million of cash and cash equivalents and $116.4 million of marketable securities.
- Total assets were $217.3 million, total liabilities were $47.7 million, and stockholders’ equity was $169.6 million.
- Accumulated deficit was $264.9 million.
- There was no long-term debt at September 30, 2020. The company prepaid its $10.0 million term loan in June 2020 and recorded a $0.6 million loss on early repayment.
- Cash provided by financing activities was $120.6 million, primarily from a $105.5 million public equity offering, $23.2 million of ATM proceeds, and $2.5 million from employee equity issuances, partly offset by debt repayment.
Material Changes Versus Prior Comparable Period
- Third-quarter revenue increased $9.0 million, or 217%, from $4.1 million to $13.1 million. The increase primarily reflected updated estimates of remaining services under the Janssen agreement and continued service delivery.
- Nine-month revenue increased $25.5 million, from $(2.5) million in 2019 to $23.0 million in 2020. The 2019 amount was reduced by a $9.4 million cumulative catch-up adjustment related to the Janssen amendment.
- Third-quarter net loss improved by $8.6 million, from $(16.4) million to $(7.8) million. Nine-month net loss improved by $12.4 million, from $(59.7) million to $(47.3) million.
- Third-quarter research and development expense decreased 8%, primarily because of lower PTG-200, PTG-300 and PN-943 costs, partly offset by higher preclinical and discovery research spending.
- Nine-month research and development expense increased 12%, driven mainly by a $10.6 million increase in preclinical and discovery research and higher PN-943 costs, partly offset by lower PTG-200 and PTG-300 spending.
- General and administrative expense increased 22% in the quarter and 17% year to date, primarily due to higher legal, insurance and salary costs.
- Shares outstanding increased from 27.2 million at December 31, 2019 to 37.3 million at September 30, 2020, largely due to equity financings. This creates dilution risk despite improved liquidity.
- Operating cash use increased from $27.2 million to $53.6 million year to date, while financing inflows increased substantially because of the May public offering and ATM sales.
Guidance, Outlook, Risks and Unusual Items
- Management expects continuing losses and significant research, development and administrative expenses and anticipates needing substantial additional capital to advance clinical programs and fund operations.
- Based on its current operating plan, management stated that existing cash, cash equivalents, marketable securities and access to the debt facility should fund operations for at least the next 12 months. This assessment depends on assumptions that may prove incorrect.
- Because of COVID-19, the company suspended guidance on timelines for the PTG-200 Phase 2 study and PN-943 Phase 2 study. The pandemic has caused clinical-trial delays and may further affect enrollment, site operations, supply chains, employees and collaboration activities.
- The company expected to begin a Phase 1 study of PN-235 in the fourth quarter of 2020. It selected polycythemia vera as the first indication for a potential PTG-300 pivotal study targeted to begin in 2021, subject to development and regulatory progress.
- The Janssen agreement provides potential future opt-in, development, regulatory and sales milestones of up to $1.0 billion and tiered royalties, but these amounts depend on future clinical, regulatory and commercial achievements and are not assured.
- Janssen revenue recognition relies on estimates of transaction price, remaining costs and percentage of completion. The estimated transaction price for the initial performance obligation decreased from $113.9 million at June 30, 2020 to $99.4 million at September 30, 2020.
- The company initiated arbitration against Zealand Pharma concerning potential milestone and royalty obligations related to PTG-300. It seeks repayment of $1.0 million previously paid; Zealand disputes the claims and has asserted counterclaims. Management assessed the probability of loss as remote and recorded no accrual.
- In May 2020, the company implemented a reduction in force affecting approximately 12% of employees, with approximately $0.3 million of severance and benefit costs.
- After quarter-end, the company sold 917,879 shares through its ATM facility for net proceeds of $18.9 million.
- Key risks include clinical failure, regulatory uncertainty, reliance on Janssen and other third parties, manufacturing and supply interruptions, intellectual-property challenges, future financing and dilution, and the absence of product revenue.
Investor Verification Priorities
- Verify the sustainability and timing of Janssen-related revenue, including the impact of changes in estimated remaining services and the $20.9 million deferred-revenue balance at September 30, 2020.
- Assess whether the reported approximately $200.0 million liquidity position is sufficient under scenarios involving COVID-19 delays, increased clinical costs or reduced collaboration receipts.
- Track enrollment, safety, efficacy and regulatory milestones for PTG-300, PN-943, PTG-200, PN-235 and PN-232.
- Review the potential financial consequences and timing of the Zealand arbitration, including possible milestone and royalty obligations.
- Monitor additional equity issuance, ATM activity and dilution, including the post-quarter-end $18.9 million ATM financing.
- Confirm the availability and conditions of the remaining debt facility, noting that the previously funded term loan had been fully repaid and future draws were subject to clinical milestones and other conditions.